Literature DB >> 34269841

Successful deprescribing of proton pump inhibitors with a patient-centered process: the DESPIBP Project.

Lamuela L J Calvo1, P García Cámara1, M Llorente Barrio1, O Sierra Gabarda1,2, R Monzón Baez1, J M Arbonés Mainar2,3, J Alcedo González1,2, V Bernal Monterde4,5.   

Abstract

BACKGROUND: Proton-pump inhibitors (PPIs) are among the most frequently prescribed drugs, but they are being overprescribed.
OBJECTIVE: To evaluate the applicability of a deprescription algorithm in hospitalized patients with chronic PPI use.
METHODS: A prospective study including consecutive gastroenterology department hospitalized patients with chronic PPI use. The prescription was reassessed and a deprescribing algorithm was applied. Follow-up was carried out at 4, 12, and 24 weeks.
RESULTS: A total of 513 (44.22%) of 1160 had chronic PPI use; 371 met inclusion criteria and were evaluated: 285 (76.82%) with appropriate prescription and 86 (23.18%) with inappropriate, mainly (52.30%) due to polypharmacy. Seventy-five patients accepted the deprescribing process. Sixty-one (81.33%) maintained deprescription at week 4, 56 (74.66%) at week 12, and 54 (72.00%) at week 24. Eleven of 21 restarted the PPI because of symptoms. No differences were found between the successful deprescription group and the unsuccessful one, regarding sex (p = 0.877), age (p = 0.635), PPI indication (p = 0.663), or deprescription regimen (p = 0.805). No patient had any adverse event attributable to deprescription.
CONCLUSION: There is a high inappropriate indication for PPIs in patients admitted to the gastroenterology department. The application of a patient-centered deprescribing algorithm is a safe and effective strategy to reduce their inappropriate consumption in the medium term.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Deprescribing; Discontinuation. Proton pump inhibitors; Hospitalization; Inappropriate prescriptions

Mesh:

Substances:

Year:  2021        PMID: 34269841     DOI: 10.1007/s00228-021-03186-x

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  7 in total

1.  Overuse of acid-suppressive therapy in hospitalized patients.

Authors:  R J Nardino; R J Vender; P N Herbert
Journal:  Am J Gastroenterol       Date:  2000-11       Impact factor: 10.864

2.  Deprescribing Proton Pump Inhibitors.

Authors:  Peter J Zed
Journal:  Can J Hosp Pharm       Date:  2018-10-31

3.  Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline.

Authors:  Barbara Farrell; Kevin Pottie; Wade Thompson; Taline Boghossian; Lisa Pizzola; Farah Joy Rashid; Carlos Rojas-Fernandez; Kate Walsh; Vivian Welch; Paul Moayyedi
Journal:  Can Fam Physician       Date:  2017-05       Impact factor: 3.275

4.  Glad you brought it up: a patient-centred programme to reduce proton-pump inhibitor prescribing in general medical practice.

Authors:  Jill Murie; Jane Allen; Ray Simmonds; Carl de Wet
Journal:  Qual Prim Care       Date:  2012

5.  Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting.

Authors:  Joel J Heidelbaugh; Kathleen L Goldberg; John M Inadomi
Journal:  Am J Manag Care       Date:  2010-09       Impact factor: 2.229

Review 6.  Polypharmacy: Evaluating Risks and Deprescribing.

Authors:  Anne D Halli-Tierney; Catherine Scarbrough; Dana Carroll
Journal:  Am Fam Physician       Date:  2019-07-01       Impact factor: 3.292

7.  Outcome after Discontinuation of Proton Pump Inhibitors at a Residential Care Site: Quality Improvement Project.

Authors:  Candy Lee; Anita Lo; Kiran Ubhi; Michael Milewski
Journal:  Can J Hosp Pharm       Date:  2017-06-30
  7 in total
  1 in total

1.  Impact of Specialized Clinics on Medications Deprescribing in Older Adults: A Pilot Study in Ambulatory Care Clinics in a Teaching Hospital.

Authors:  Ghada Bawazeer; Saad Alsaad; Haya Almalag; Alhanouf Alqahtani; Noura Altulaihi; Abdulaziz Alodhayani; Abdulaziz AlHossan; Ibrahim Sales
Journal:  Saudi Pharm J       Date:  2022-04-30       Impact factor: 4.562

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.